Femtech Startup Funding 2025-2026

What are all the funding deals in the femtech market from August 2025 to July 2026?

The table below lists every disclosed equity or equity-like round raised by pure-play femtech companies between August 2025 and July 2026. We count as pure-play femtech companies those focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of the opportunity, we cover it in our Femtech market report.

How active has fundraising been in the femtech market?

As of July 2026, fundraising in the femtech market has been active by deal count but moderate by total capital. Over the past 12 months, the dataset includes 27 disclosed equity or equity-like deals and $445.53M raised.

That equals an average of 2.45 deals per month, with a median of 2.00 deals per month. The market therefore shows regular activity, not just one isolated funding burst.

Monthly capital is less stable. The average month produced $40.50M, but the median was $39.00M, and February 2026 alone contributed $100.00M through Midi Health.

The strongest deal-flow months were September 2025, March 2026, and June 2026, each with 5 deals. Those months show that activity is spread across the period, even if dollars remain spiky.

For a deeper view of the companies behind this activity, see our femtech market report.

How concentrated has fundraising been in the femtech market?

As of July 2026, fundraising in the femtech market has been meaningfully concentrated at the top. Over the past 12 months, the largest deal accounted for 22.45% of all disclosed capital.

The top 3 deals accounted for 44.09% of total funding, while the top 5 reached 61.15%. This means more than half of all capital came from only five companies.

The top 10 deals accounted for 82.38% of total funding. That is a strong signal that the femtech market’s dollar story is shaped by a small number of large clinical or platform rounds.

This concentration matters because the deal-count picture looks more balanced. A reader should separate the number of funded companies from the dollars captured by the biggest winners.

How much of the femtech funding signal is driven by outliers?

As of July 2026, the femtech funding signal is partly driven by outliers, but not entirely dependent on them. Over the past 12 months, total capital was $445.53M, and capital excluding rounds above $50M was $345.53M.

Midi Health’s $100.00M Series D+ is the clearest outlier. It alone represents 22.45% of total disclosed capital and materially changes the optics of hormonal health and late-stage funding.

Only two rounds reached $50M or more: Midi Health at $100.00M and Conceivable Life Sciences at $50.00M. The market therefore has some scaling evidence, but not a deep pool of megarounds.

The median round size of $8.00M is the better reading of typical market conditions. The $16.50M average is useful, but it is lifted by a few larger financings.

Is the femtech market broad with many targets, or narrow with few fundable companies?

As of July 2026, the femtech market looks broad by category coverage but still narrow by scaled venture outcomes. Over the past 12 months, the dataset includes 27 deals across 27 unique companies.

No company raised twice in the disclosed sample, which means visible activity is distributed across different teams. That is a different pattern from markets where repeat fundraisers dominate deal count.

However, dollars remain narrow. The top 10 deals captured 82.38% of all capital, so many companies raised small or mid-sized rounds while a few platforms captured most investor conviction.

The category spread is real. Fertility Care Platforms, Hormonal Health Platforms, and Women’s Primary Care each produced 6 deals, showing that the femtech market is not only a fertility market.

Is femtech mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the femtech market is balanced between early-stage formation and selective late-stage scaling. Over the past 12 months, early-stage rounds raised $172.98M, while Series C and Series D+ rounds raised $176.00M.

Early stage, defined as pre-seed, seed, and Series A, represented 38.83% of total capital. That shows strong company formation across fertility, maternal care, diagnostics, and women’s primary care.

Late stage represented 39.50% of total capital, but came from only a few known larger rounds. Midi Health and Gameto are especially important to this part of the market.

The unknown-stage bucket is also large, with 7 deals and $96.55M. That means the femtech market still has uneven disclosure standards, especially compared with more mature venture categories.

We break down this stage mix further in our market report on femtech funding.

Which categories attract the most investor attention in femtech?

As of July 2026, Fertility Care Platforms, Hormonal Health Platforms, and Women’s Primary Care attract the most investor attention by deal count. Over the past 12 months, each category produced 6 disclosed deals.

By capital raised, Hormonal Health Platforms lead the femtech market. The category raised $169.56M, equal to 38.06% of all disclosed funding.

Fertility Care Platforms ranked second by dollars, with $133.73M and 30.02% of total capital. Together, hormonal health and fertility captured 68.08% of all disclosed funding.

Women’s Primary Care is active but less capital-intensive. It matched the leaders with 6 deals, yet raised only $42.99M, equal to 9.65% of total capital.

Which categories attract disproportionately large checks in the femtech market?

As of July 2026, Hormonal Health Platforms attract the most disproportionately large checks in the femtech market. Over the past 12 months, the category captured 38.06% of capital from only 22.22% of deals.

Its capital share to deal share ratio is 1.71, the highest in the dataset. Midi Health’s $100.00M round is the main driver, but SheMed and Clair Health also support the category’s scale signal.

Fertility Care Platforms also punch above their deal share. The category captured 30.02% of capital from 22.22% of deals, giving it a ratio of 1.35.

Pregnancy Care Solutions and Women’s Primary Care show the opposite pattern. They have meaningful deal activity but lower average check sizes, which suggests investors are still testing care models and reimbursement depth.

Which geographies matter most for fundraising in the femtech market?

As of July 2026, North America matters most for femtech fundraising by both capital and deal count. Over the past 12 months, North America produced 17 deals and $326.55M raised.

That equals 62.96% of all deals and 73.29% of total disclosed capital. North America’s capital share is higher than its deal share, which means its rounds are larger on average.

Asia-Pacific ranked second by deal count, with 5 deals and $53.10M raised. Europe ranked second by capital, with $59.88M raised across 4 deals.

The Middle East appeared through one deal, Feminai’s $6.00M seed round. Latin America and Africa had no qualifying disclosed pure-play rounds in this dataset.

For more context on regional opportunities, see our deeper analysis of the femtech market.

Is the femtech opportunity set broad or concentrated in one hub?

As of July 2026, the femtech opportunity set is broad in health needs but geographically concentrated in one leading hub. Over the past 12 months, North America held 73.29% of disclosed capital.

North America also held 62.96% of deals, which makes it the only region with both breadth and scale. Its average deal size was $19.21M, above Europe and Asia-Pacific.

Europe has a smaller but visible role. Its 4 deals raised $59.88M, helped by SheMed and Emm, and its average round size reached $14.97M.

Asia-Pacific shows more formation than scaling. It produced 5 deals but a median deal size of $4.00M, suggesting more local-market and consumer-health activity than large global platform financing.

Is femtech a market of small experiments or scaled financings?

As of July 2026, femtech is still more a market of small and mid-sized financings than a market of scaled megarounds. Over the past 12 months, 19 of 27 deals were below $20M.

The largest bucket was $5M to $20M, with 10 deals. Another 9 deals were below $5M, showing that much of the femtech market is still in formation mode.

There were 6 deals between $20M and $50M and 2 deals of $50M or more. That distribution shows selective scaling, not broad late-stage liquidity.

The median deal size was $8.00M, which is the cleanest read on the typical round. The market has visible winners, but the average company is still raising modest capital.

We cover the size distribution in more detail in our full market deck on femtech.

Who are the investors that appear the most in femtech fundraising?

As of July 2026, the most frequent femtech investors are mostly specialist, women’s health-focused, or thesis-driven funds. Over the past 12 months, several investors appeared in more than one disclosed deal.

Overwater Ventures appeared in Gameto and BeSound. Emmeline Ventures appeared in Prickly Pear Health and Osteoboost Health, while Coyote Ventures appeared in Malama Health and HealthFab.

Portfolia appeared in Gameto and Osteoboost Health. Rogue Women’s Fund and Zeal Capital Partners both appeared in Seven Starling and Flourish Care.

ARTIS appeared in Conceivable Life Sciences and ONTO Health, linking two fertility-related platform bets. FemHealth Ventures appeared around Rejoni and broader women’s health investor participation where disclosed.

One caveat matters: announcements usually disclose round size, not each investor’s check. Investor frequency is therefore more reliable than dollar contribution by investor.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.